MedTrace Logo

uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer

NCT02960724 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2016-11-10

No results posted yet for this study

Summary

uPAR PET/CT for Staging Advanced and Localised oral and oropharyngeal cancer

Conditions

  • Oral Cancer
  • Oropharyngeal Cancer
  • Neoplasms
  • Head and Neck Neoplasms
  • Cancer of Mouth
  • Neoplasms by Site

Interventions

OTHER

68Ga-NOTA-AE105 PET/CT

One injection of 68Ga-NOTA-AE105 (app. 200 Mbq) followed by Positron Emission Tomography Scan.

Sponsors & Collaborators

  • Rigshospitalet, Denmark

    lead OTHER

Principal Investigators

  • Andreas Kjær, MD,DMSc,PhD · Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2018-08-31
Completion
2018-08-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02960724 on ClinicalTrials.gov